Dual antithrombotic therapy in PCI: Potential harm in routine adoption

Area of Science:

• Cardiology
• Clinical Practice Research
• Thrombosis Management

Background:

• Dual antithrombotic therapy (DAT) is supported by randomized trials for percutaneous coronary intervention (PCI) patients.
• Clinical outcomes of DAT in real-world practice, especially in high-risk populations, remain unclear.

Discussion:

• This observational study compared P2Y12 inhibitor monotherapy with dual antiplatelet therapy (DAPT) plus oral anticoagulation (OAC) in high-risk patients.
• Routine P2Y12 inhibitor monotherapy was linked to increased ischemic events and no reduction in bleeding compared to DAPT with OAC.

Key Insights:

• In high-risk PCI patients, P2Y12 inhibitor monotherapy may not be sufficient to prevent ischemic events compared to DAPT with OAC.
• The study suggests a potential trade-off between ischemic risk and bleeding risk that needs careful consideration in clinical practice.

Outlook:

• Further randomized trials are essential to define the optimal patient population for DAT.
• Large registry analyses are needed to validate these findings and inform clinical decision-making for antithrombotic strategies.